Under the terms of this license agreement, Nippon Shinyaku will receive from Actelion an upfront payment and additional milestone payments based on development stage and sales achievement. Nippon Shinyaku will also receive royalties on sales. In addition, this agreement enables Nippon Shinyaku to explore the possibility of co-development in Japan of a compound which is being developed by Actelion globally.
In order to promptly bring NS-304 to the market of pulmonary arterial hypertension and other possible indications, Actelion will take over the Phase IIa clinical study being conducted by Nippon Shinyaku in Europe and be responsible for global development and commercialization of NS-304 outside Japan. The two companies will co-develop and co-commercialize NS-304 in Japan.